Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | NHS England |
| Main Category: | Goods |
| Procurement Method: | Call-off from a framework agreement |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): | £2,607,802 |
| Release Date: | 12 March 2026 |
| Application Deadline: | 12 March 2026 |
| Contract Start Date: | 31 March 2026 |
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to
| Award value: | £4,074,117 |
| Award decision date: | 25 March 2026 |
| Award status: | Active |
EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).
Published contracts in the last 12 months
2,046
total contracts
£179666.3m
total value
£251,986,446
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
12 March 2026
Closed
Estimated Value
£2,607,802
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Contract End Date: |
| 31 March 2029 |
| Contract Duration: | 3.1 years |
| Procurement ID (OCID): | ocds-b5fd17-63bc49a4-6875-44ee-bcf1-d9ea348f4445 |
| Notice Reference: | d1d6ec3d-8b57-42c2-bcc9-988c98df5b88-888234 |